MedTrace Logo

I-123 Brain Studies of Serotonin Metabolism in Psychiatric Patients and Normal Volunteers

NCT00001771 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 112

Last updated 2008-03-04

No results posted yet for this study

Summary

Abnormalities in the re-uptake of dopamine and serotonin have been described in various neuropsychiatric disorders and substance abuse. \[I-123\] Beta-CIT is a recently developed radioligand for SPECT imaging of dopamine and serotonin transporters. \[I-123\]Beta-CIT SPECT has been used at the SPECT-lab of the Clinical Brain Disorders Branch in over fifty subjects without adverse events. Due to the trace concentrations used, a pharmacological effect of Beta-CIT is unlikely and has not been observed. The purpose of this study is to use Beta-CIT and SPECT to study the expression of dopamine and serotonin transporters in vivo in normal controls and various patient populations to address hypothesized abnormalities of the transporters in different disorders and to understand the effects of genetic variations in the genes of these transporters on their in vivo expression.

Conditions

  • Healthy
  • Mental Disorder
  • Obsessive Compulsive Disorder
  • Schizophrenia
  • Tourette Syndrome

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    lead NIH

Eligibility

Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
1998-05-31
Completion
2003-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00001771 on ClinicalTrials.gov